$RENE
Cartesian Growth Corp II

2022 Q4 Form 10-K Financial Statement

#000119312523085522 Filed on March 30, 2023

View on sec.gov

Income Statement

Concept 2022 Q4 2022 2021 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $203.6K $685.1K
YoY Change -81.63%
Operating Profit -$685.1K -$3.727K
YoY Change
Interest Expense $1.794M $2.846M
YoY Change
% of Operating Profit
Other Income/Expense, Net -$2.159M $5.614M $0.00
YoY Change
Pretax Income -$569.2K $4.929M
YoY Change -232.13%
Income Tax
% Of Pretax Income
Net Earnings -$569.2K $4.929M -$3.727K
YoY Change 15171.0% -232.13%
Net Earnings / Revenue
Basic Earnings Per Share $0.24 $0.00
Diluted Earnings Per Share -$0.02 $0.24 $0.00
COMMON SHARES
Basic Shares Outstanding 5.484M 5.750M
Diluted Shares Outstanding 5.750M 5.750M

Balance Sheet

Concept 2022 Q4 2022 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $543.7K $543.7K
YoY Change
Cash & Equivalents $543.7K $543.7K $0.00
Short-Term Investments
Other Short-Term Assets $306.7K $306.7K
YoY Change -99.93%
Inventory
Prepaid Expenses $306.7K
Receivables
Other Receivables
Total Short-Term Assets $850.4K $850.4K
YoY Change -99.82%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $239.7M $239.7M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $239.7M $239.7M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $850.4K $850.4K
Total Long-Term Assets $239.7M $239.7M
Total Assets $240.6M $240.6M $463.6K
YoY Change 51794.15% -48.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $148.9K $218.9K $303.9K
YoY Change -51.0% -99.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $218.9K $218.9K $442.4K
YoY Change -50.51% -99.95%
LONG-TERM LIABILITIES
Long-Term Debt $3.343M $3.343M
YoY Change
Other Long-Term Liabilities $3.827M $3.827M
YoY Change
Total Long-Term Liabilities $7.170M $7.170M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $218.9K $218.9K $442.4K
Total Long-Term Liabilities $7.170M $7.170M
Total Liabilities $18.89M $18.89M $442.4K
YoY Change 4169.99% -95.73%
SHAREHOLDERS EQUITY
Retained Earnings -$18.04M -$3.727K
YoY Change 483900.91%
Common Stock $0.00 $24.43K
YoY Change -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$18.04M $221.7M $21.27K
YoY Change
Total Liabilities & Shareholders Equity $240.6M $240.6M $463.6K
YoY Change 51794.15% -48.1%

Cashflow Statement

Concept 2022 Q4 2022 2021 Q4
OPERATING ACTIVITIES
Net Income -$569.2K $4.929M -$3.727K
YoY Change 15171.0% -232.13%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$111.9K -$842.9K $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$236.9M
YoY Change
Cash From Investing Activities $0.00 -$236.9M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $225.4M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -5.000K 238.3M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -111.9K -842.9K 0.000
Cash From Investing Activities 0.000 -236.9M 0.000
Cash From Financing Activities -5.000K 238.3M 0.000
Net Change In Cash -116.9K 543.7K 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$111.9K -$842.9K $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001889112
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-41378
CY2022 dei Entity Registrant Name
EntityRegistrantName
CARTESIAN GROWTH CORPORATION II
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
505 Fifth Avenue
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
15th Floor
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
CY2022 dei City Area Code
CityAreaCode
212
CY2022 dei Local Phone Number
LocalPhoneNumber
461-6363
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
true
CY2022Q2 dei Entity Public Float
EntityPublicFloat
230500000
CY2022 dei Auditor Firm
AuditorFirmId
688
CY2022 dei Auditor Name
AuditorName
Marcum LLP
CY2022 dei Auditor Location
AuditorLocation
West Palm Beach, FL
us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants
CY2022Q4 us-gaap Cash
Cash
543667
CY2021Q4 us-gaap Cash
Cash
0
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
306733
CY2022Q4 us-gaap Assets Current
AssetsCurrent
850400
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
463629
CY2022Q4 rene Cash And Marketable Securities Held In Trust Account
CashAndMarketableSecuritiesHeldInTrustAccount
239745907
CY2022Q4 us-gaap Assets
Assets
240596307
CY2021Q4 us-gaap Assets
Assets
463629
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
148911
CY2022Q4 rene Accrued Offering Costs
AccruedOfferingCosts
70000
CY2021Q4 rene Accrued Offering Costs
AccruedOfferingCosts
303895
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
138461
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
218911
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
442356
CY2022Q4 rene Warrant Liabilities Non Current
WarrantLiabilitiesNonCurrent
3826696
CY2022Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
3342932
CY2022Q4 rene Deferred Underwriting Fee Non Current
DeferredUnderwritingFeeNonCurrent
11500000
CY2022Q4 us-gaap Liabilities
Liabilities
18888539
CY2021Q4 us-gaap Liabilities
Liabilities
442356
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 rene Ordinary Shares Subject To Possible Redemption Value
OrdinarySharesSubjectToPossibleRedemptionValue
239745907
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
CY2022Q4 rene Common Stock Value1
CommonStockValue1
575
CY2021Q4 rene Common Stock Value1
CommonStockValue1
575
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
24425
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18038714
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3727
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-18038139
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
21273
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
240596307
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
463629
CY2022 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
685056
CY2021Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
3727
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-685056
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3727
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1706572
CY2021Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022 rene Change In Fair Value Of Convertible Promissory Note Related Party
ChangeInFairValueOfConvertiblePromissoryNoteRelatedParty
-1257068
CY2021Q4 rene Change In Fair Value Of Convertible Promissory Note Related Party
ChangeInFairValueOfConvertiblePromissoryNoteRelatedParty
0
CY2022 rene Transaction Costs Allocated To Warrant Liabilities
TransactionCostsAllocatedToWarrantLiabilities
195984
CY2021Q4 rene Transaction Costs Allocated To Warrant Liabilities
TransactionCostsAllocatedToWarrantLiabilities
0
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
2845907
CY2021Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
0
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5613563
CY2021Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
4928507
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-3727
CY2022 rene Basic Weighted Average Shares Outstanding Shares Subject To Possible Redemption
BasicWeightedAverageSharesOutstandingSharesSubjectToPossibleRedemption
14871233
CY2022 rene Diluted Weighted Average Shares Outstanding Shares Subject To Possible Redemption
DilutedWeightedAverageSharesOutstandingSharesSubjectToPossibleRedemption
14871233
CY2021Q4 rene Basic Weighted Average Shares Outstanding Shares Subject To Possible Redemption
BasicWeightedAverageSharesOutstandingSharesSubjectToPossibleRedemption
0
CY2021Q4 rene Diluted Weighted Average Shares Outstanding Shares Subject To Possible Redemption
DilutedWeightedAverageSharesOutstandingSharesSubjectToPossibleRedemption
0
CY2022 rene Basic Net Income Per Ordinary Share Shares Subject To Possible Redemption
BasicNetIncomePerOrdinaryShareSharesSubjectToPossibleRedemption
0.24
CY2022 rene Diluted Net Income Per Ordinary Share Shares Subject To Possible Redemption
DilutedNetIncomePerOrdinaryShareSharesSubjectToPossibleRedemption
0.24
CY2021Q4 rene Basic Net Income Per Ordinary Share Shares Subject To Possible Redemption
BasicNetIncomePerOrdinaryShareSharesSubjectToPossibleRedemption
0
CY2021Q4 rene Diluted Net Income Per Ordinary Share Shares Subject To Possible Redemption
DilutedNetIncomePerOrdinaryShareSharesSubjectToPossibleRedemption
0
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5484203
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5750000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.24
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5750000
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5750000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.24
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
0
CY2021Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-3727
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
21273
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
5927400
CY2022 rene Adjustments To Additional Paid In Capital Remeasurement For Ordinary Shares To Redemption Amount
AdjustmentsToAdditionalPaidInCapitalRemeasurementForOrdinarySharesToRedemptionAmount
-28915319
CY2022 us-gaap Profit Loss
ProfitLoss
4928507
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-18038139
CY2022 us-gaap Profit Loss
ProfitLoss
4928507
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-3727
CY2022 rene Formation Cost Paid By The Sponsor
FormationCostPaidByTheSponsor
0
CY2021Q4 rene Formation Cost Paid By The Sponsor
FormationCostPaidByTheSponsor
-3727
CY2022 rene Interest Earned On Cash And Marketable Securities Held In Trust Account
InterestEarnedOnCashAndMarketableSecuritiesHeldInTrustAccount
2845907
CY2021Q4 rene Interest Earned On Cash And Marketable Securities Held In Trust Account
InterestEarnedOnCashAndMarketableSecuritiesHeldInTrustAccount
0
CY2022 rene Transaction Costs
TransactionCosts
195984
CY2021Q4 rene Transaction Costs
TransactionCosts
0
CY2022 rene Change In Fair Value Of Convertible Promissory Note Related Party
ChangeInFairValueOfConvertiblePromissoryNoteRelatedParty
-1257068
CY2021Q4 rene Change In Fair Value Of Convertible Promissory Note Related Party
ChangeInFairValueOfConvertiblePromissoryNoteRelatedParty
0
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1706572
CY2021Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022 rene Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
306733
CY2021Q4 rene Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
0
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
148911
CY2021Q4 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-842878
CY2021Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0
CY2022 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
236900000
CY2021Q4 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
0
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-236900000
CY2021Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
225400000
CY2021Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
8900000
CY2021Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
77944
CY2021Q4 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
216405
CY2021Q4 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4600000
CY2021Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
474994
CY2021Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
238286545
CY2021Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
543667
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
0
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
543667
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
CY2022 rene Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
11500000
CY2021Q4 rene Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
0
CY2022 rene Remeasurement Of Ordinary Shares Subject To Possible Redemption
RemeasurementOfOrdinarySharesSubjectToPossibleRedemption
28915319
CY2021Q4 rene Remeasurement Of Ordinary Shares Subject To Possible Redemption
RemeasurementOfOrdinarySharesSubjectToPossibleRedemption
0
CY2022 rene Offering Costs Included In Accrued Offering Costs
OfferingCostsIncludedInAccruedOfferingCosts
70000
CY2021Q4 rene Offering Costs Included In Accrued Offering Costs
OfferingCostsIncludedInAccruedOfferingCosts
0
CY2022 us-gaap Stock Issued1
StockIssued1
0
CY2021Q4 us-gaap Stock Issued1
StockIssued1
21273
CY2022 us-gaap Notes Issued1
NotesIssued1
0
CY2021Q4 us-gaap Notes Issued1
NotesIssued1
138461
CY2022 rene Deferred Offering Costs Included In Accrued Offerings Costs And Expenses
DeferredOfferingCostsIncludedInAccruedOfferingsCostsAndExpenses
0
CY2021Q4 rene Deferred Offering Costs Included In Accrued Offerings Costs And Expenses
DeferredOfferingCostsIncludedInAccruedOfferingsCostsAndExpenses
303895
CY2022Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
23000000
CY2022 rene Public Share Price Per Share
PublicSharePricePerShare
10.3
CY2022 us-gaap Interest Expense Other
InterestExpenseOther
100000
CY2022 rene Public Share Price Per Share
PublicSharePricePerShare
10.3
CY2022Q4 us-gaap Cash
Cash
543667
CY2022Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
239745907
CY2022Q4 rene Working Capital
WorkingCapital
631489
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div>
CY2022Q4 us-gaap Cash
Cash
543667
CY2021Q4 us-gaap Cash
Cash
0
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
0
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. </div>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022 rene Offering Costs
OfferingCosts
16804728
CY2022 rene Offering Costs Charged To Shareholders Deficit
OfferingCostsChargedToShareholdersDeficit
16608744
CY2022 rene Offering Costs Charged To Operations
OfferingCostsChargedToOperations
195984
CY2022 rene Dissolution Expenses
DissolutionExpenses
100000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2022 us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Financial Instruments</div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging – Contracts in Entity’s Own Equity” (“ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40”).</div> The Company’s derivative instruments are recorded at fair value on the balance sheet with changes in the fair value reported in the statement of operations. Derivative assets and liabilities are classified on the balance sheet as current or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> based on whether or not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">net-cash</div> settlement or conversion of the instrument could be required within 12 months of the balance sheet date. </div>
CY2022 rene Warrant Description
WarrantDescription
The warrants will become exercisable on the later of 12 months from the closing of the Initial Public Offering or 30 days after the completion of the Company’s initial Business Combination, and will expire five years after the completion of the Company’s initial Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.
CY2022 rene Percentage Of Proceeds From Share Issuances
PercentageOfProceedsFromShareIssuances
0.60
CY2021Q4 us-gaap Sponsor Fees
SponsorFees
25000
CY2021Q4 rene Price Per Share Unit
PricePerShareUnit
0.004
CY2021Q4 rene Assets Tangible And Intangible
AssetsTangibleAndIntangible
0
CY2021Q4 rene Percentage Of Founder Shares
PercentageOfFounderShares
0.20
CY2022 rene Business Combination Description
BusinessCombinationDescription
The Sponsor and DirectorCo have agreed not to transfer, assign or sell any of the founder shares (except to certain permitted transferees) until one year after the date of the completion of the initial Business Combination or earlier if, subsequent to the initial Business Combination, (i) the last reported sale price of the Class A Ordinary Shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, reorganizations and recapitalizations) for any 20 trading days within any30-tradingday period commencing at least 150 days after the initial Business Combination, or (ii) the Company consummates a subsequent liquidation, merger, share exchange or other similar transaction which results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property.
rene Office Space Monthly Rent
OfficeSpaceMonthlyRent
10000
CY2022Q4 rene Working Capital Loan
WorkingCapitalLoan
1500000
CY2022 rene Price Per Warrant
PricePerWarrant
1
CY2022 rene Registration Rights Description
RegistrationRightsDescription
The holders of the majority of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until termination of the applicable lock-up period, which occurs (i) in the case of the founder shares, one year after the date of the completion of the initial Business Combination or earlier if, subsequent to the initial Business Combination, the last reported sale price of the Class A Ordinary Shares equals or exceeds $12.00 per share (as adjusted for share splits, share dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or the Company consummates a subsequent liquidation, merger, share exchange or other similar transaction which results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property, and (ii) in the case of the Private Placement Warrants and the respective Class A Ordinary Shares underlying such Private Placement Warrants, 30 days after the completion of the initial Business Combination.
CY2022 rene Number Of Demands Eligible Security Holder Can Make
NumberOfDemandsEligibleSecurityHolderCanMake
3
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022 us-gaap Sale Of Stock Percentage Of Ownership Before Transaction
SaleOfStockPercentageOfOwnershipBeforeTransaction
0.20
CY2022Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
16566666
rene Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Initial Measurement
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInitialMeasurement
5533268
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-680330
rene Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 To Level1
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3ToLevel1
-2750475
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2102463
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0

Files In Submission

Name View Source Status
rene-20221231_cal.xml Edgar Link unprocessable
0001193125-23-085522-index-headers.html Edgar Link pending
0001193125-23-085522-index.html Edgar Link pending
0001193125-23-085522.txt Edgar Link pending
0001193125-23-085522-xbrl.zip Edgar Link pending
d367373d10k.htm Edgar Link pending
d367373dex311.htm Edgar Link pending
d367373dex312.htm Edgar Link pending
d367373dex321.htm Edgar Link pending
d367373dex45.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
d367373d10k_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rene-20221231.xsd Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
rene-20221231_def.xml Edgar Link unprocessable
rene-20221231_lab.xml Edgar Link unprocessable
rene-20221231_pre.xml Edgar Link unprocessable